Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 6/20 | 1.00 |
| ▸ | EGFR | P00533 | 14/20 | 0.98 |
| ▸ | LCK | P06239 | 1/20 | 0.76 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.73 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5482884 | 0.88 | EGFR (1.00) | FBP1EGFRLCKERBB2 | |
| SCHEMBL14551678 | 0.87 | FBP1 (0.77) | FBP1EGFRLCKERBB2ERBB4 | |
| SCHEMBL2100996 | 0.86 | EGFR (0.77) | FBP1EGFRERBB2ERBB4 | |
| Hydrochloric Acid SCHEMBL5475745 | 0.86 | EGFR (1.00) | FBP1EGFRLCKERBB2ERBB4 | |
| SCHEMBL5565577 | 0.85 | FGFR1 (0.78) | FBP1EGFRERBB2ERBB4 | |
| SCHEMBL5606140 | 0.85 | FBP1 (1.00) | FBP1EGFRLCKERBB2ERBB4 | |
| SCHEMBL3008965 | 0.85 | FBP1 (1.00) | FBP1EGFRERBB2ERBB4 | |
| SCHEMBL8594529 | 0.85 | EGFR (0.79) | FBP1EGFRERBB2ERBB4 | |
| Hydrochloric Acid SCHEMBL3258223 | 0.84 | EGFR (0.75) | FBP1EGFRERBB2ERBB4 | |
| SCHEMBL668572 | 0.83 | EGFR (0.81) | FBP1EGFRLCKERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6638939-B2 | Anticancer agents | PARKER HUGHES INSTITUTE | 2003-10-28 | — | — | US | disclosed |
| US-20020137757-A1 | Quinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE (US) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137757-A1 | Quinazolines and therapeutic use thereof | HRH2, HRH4, HNMT | FBP1 3422/4885EGFR 1931/4885LCK 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.